Compound class:
Peptide or derivative
Comment: SNG001 is a recombinant form of human interferon β, interferon beta-1a, in a formulation that can be administered via a neubliser, directly to the lungs. Synairgen originally developed SNG001 as a therapy for virally-induced exacerbations of COPD, but have rapidly re-deployed it for SARS-CoV-2 infection. The EU Clinical Trials Register entry for Synairgen's study of SNG001 in COVID-19 patients (EudraCT Number: 2020-001023-14) contains the detail that SNG001 is "Interferon beta-1a".
|
| No information available. |
Summary of Clinical Use  |
| SNG001 has progressed to clinical evaluation, for potential to reduce viral infection-induced exacerbations in patients with asthma or COPD, and has been rapidly re-deployed for COVID-19. Phase 2 (NCT04385095) safety and efficacy data was published in November 2020 [1]. This study found that, compared to placebo, SNG001 reduced time to recovery and increased chances of of improvement in hospitalised COVID-19 patients. The results warrant progressing SNG001 to larger scale trials. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01126177 | Comparing Efficacy and Safety of Inhaled SNG001 to Placebo | Phase 2 Interventional | Synairgen Research Ltd. | ||
| NCT03570359 | A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza | Phase 2 Interventional | Synairgen Research Ltd. | ||
| NCT04385095 | Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection | Phase 2 Interventional | Synairgen Research Ltd. | Safety data and positive signals of efficacy were reported in November 2020. | 1 |
